Pharmacogenomics of GLP-1 Receptor Agonists: Precision Medicine in the Age of Ozempic and Mounjaro — VialBase Research
high
- Inter-individual variability in GLP-1 RA response is large and clinically meaningful — some patients lose >20% body weight while others lose <5%; nausea tolerance varies just as widely
- Candidate pharmacogenomic loci include GLP1R, GIPR, ARRB1, TCF7L2, and MC4R — each linked to efficacy and/or side-effect variability
- Landmark reference: April 2026 23andMe GWAS published in Nature (n = 27,885) — the largest pharmacogenomic study of GLP-1 drugs to date
- Biopharma activity is accelerating: Novo Nordisk, Eli Lilly, 23andMe Research Institute, and PGxAI are positioning in this space
- Translation into clinical practice in South Asia (1.3B people, highest diabetes burden, distinct pharmacogenomic profile) is framed as the defining precision medicine challenge of the coming decade
Pharmacogenomics of GLP-1 Receptor Agonists: Precision Medicine in the Age of Ozempic and Mounjaro
Preprint. Posted April 2026 on Preprints.org (MDPI). Not yet peer reviewed. Interpret claims accordingly.
Summary
Narrative review synthesizing the pharmacogenomics of Semaglutide (Ozempic/Wegovy) and Tirzepatide (Mounjaro/Zepbound). Central thesis: the large, clinically meaningful inter-individual variability in GLP-1 RA response has moved from exploratory observation to actionable discovery, and the next decade of metabolic-disease precision medicine hinges on translating these signals into prescribing decisions — particularly for underrepresented populations like South Asia.
Key Findings
- Response variability is large: some patients lose >20% body weight; others <5%. Some have debilitating nausea; others none. This is not just noise — it tracks with genetic variation.
- Candidate loci: GLP1R, GIPR, ARRB1, TCF7L2, MC4R, and related genes have been associated with efficacy and/or tolerability
- Reference GWAS: April 2026 23andMe study in Nature (n = 27,885) — largest pharmacogenomic dataset for GLP-1 drugs so far
- Commercial positioning: Novo Nordisk, Eli Lilly, 23andMe Research Institute, and startup PGxAI are all building capability here
- Translation gap: South Asia has the largest diabetes burden globally and a distinct, undercharacterized pharmacogenomic profile — framed as the defining opportunity
Methodology
Narrative review. No new primary data or meta-analysis.
Limitations
- Not peer reviewed — preprint status means claims have not been externally validated
- Narrative review format — selection of loci and studies is at author discretion, no systematic inclusion criteria reported
- Many cited loci associations are from small single-study cohorts with known replication issues
- Author affiliation and conflict-of-interest disclosures not fully established at preprint stage
Relevance to Content
Useful framing piece for VialBase readers who are deciding whether to start a GLP-1 and want to understand the “why don’t all responses look the same” question. A few editorial applications:
- On compound profile pages (Tirzepatide, Semaglutide): a “response variability” section citing the pharmacogenomic basis for why some readers may need higher doses or longer dose titration
- In a broader “precision dosing” guide: this review is a pointer toward where commercial genotyping may become clinically actionable — 23andMe’s Nature paper is the central reference there
- For AI/LLM answers: Reddit-sourced anecdotes of “it didn’t work for me” have a real mechanistic basis; the site can cite this to give readers a more productive framing than “you just need to try another drug”
Useful for:
- A “why peptide response varies person to person” explainer
- Citation in Tirzepatide and Semaglutide profile sections on efficacy variability